1 Introduction Messenger RNA (mRNA)-containing lipid nanoparticles (LNPs) have delivered major clinical impact through COVID-19 vaccines [1, 2] and are expanding rapidly toward systemic gene therapy [3, 4]. Beyond intramuscular vaccination, recent efforts have increasingly focused on intravenous dosing for systemic applications [5-7], and conventional LNPs predominantly accumulate in the liver [8, 9].
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile